Crew Capital Management Ltd. Purchases 954 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Crew Capital Management Ltd. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,913 shares of the biopharmaceutical company’s stock after buying an additional 954 shares during the quarter. Crew Capital Management Ltd.’s holdings in Gilead Sciences were worth $398,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in GILD. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $26,000. Tompkins Financial Corp grew its stake in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Rakuten Securities Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $33,000. Finally, Financial Connections Group Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $40,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.52 during trading hours on Monday, hitting $65.94. 7,837,944 shares of the company’s stock were exchanged, compared to its average volume of 7,481,453. The stock’s 50-day moving average is $71.28 and its 200-day moving average is $76.25. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The stock has a market cap of $82.10 billion, a price-to-earnings ratio of 184.72, a price-to-earnings-growth ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a 52 week low of $64.63 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.37 earnings per share. As a group, research analysts forecast that Gilead Sciences, Inc. will post 3.82 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.67%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the subject of a number of recent analyst reports. Morgan Stanley decreased their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. Cantor Fitzgerald decreased their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. TD Cowen reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. Mizuho reduced their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Finally, Barclays reduced their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $83.60.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.